[BIO USA] CEO John Rim of Samsung Biologics: "Netherlands Base to Open in Q3"... Establishing Sales Network in Three Major Markets
Acquisition of Rockville and Groundbreaking of Sixth Plant Expand Production Capacity to 1,385,000 Liters
ADC DP Line and Third Bio Campus Construction Drive Portfolio Diversification
Establishment of 200 Billion Won Fund III Boosts Investment i
"We plan to open a European sales office in Amsterdam, the Netherlands, in the third quarter of this year. It is an optimal business hub, located at the heart of the European continent with excellent accessibility from Korea."
John Rim, CEO of Samsung Biologics, is explaining current business issues at a press conference held in San Diego, USA, on the 23rd (local time). Samsung Biologics
View original imageJohn Rim, CEO of Samsung Biologics, officially announced plans to establish a European sales base during a press conference at the '2026 BIO International Convention (BIO USA)' held in San Diego, USA, on the 23rd (local time).
Following the establishment of sales offices in New Jersey, USA in 2023 and Tokyo, Japan last year, Samsung Biologics is now expanding to the Netherlands. With this move, the company will have business hubs in all three major global biopharmaceutical markets: the United States, Europe, and Japan as well as the Asia-Pacific region. According to global market research firm Frost & Sullivan, as of last year, the United States accounted for 52% of the global biopharmaceutical market, Europe 20%, and the Asia-Pacific region 19%, with these three markets comprising about 90% of the total market share.
The company is also accelerating the expansion of its manufacturing bases. In March, Samsung Biologics completed the acquisition of its Rockville plant in the United States, increasing its total global production capacity to 845,000 liters. The Rockville plant, located on an 80,937-square-meter site, has a production capacity of 60,000 liters (two 20,000-liter lines and two 10,000-liter lines), with additional space available for future expansion. CEO John Rim stated, "With the acquisition of the Rockville plant, we have expanded our global client response capabilities and can now offer more flexible production options through a dual production system. We will continue to strengthen our order competitiveness by continuously expanding production capacity." The company expects revenue from product shipments at the Rockville plant to begin being recognized in the second quarter, with full-scale recognition starting in the third quarter. In addition, the company announced that it is reviewing strategic mergers and acquisitions (M&A) that could generate synergies with the Rockville facility.
The expansion of domestic production facilities will also continue. Samsung Biologics plans to decide within this year whether to break ground on its sixth plant (180,000 liters) and aims to complete its second Bio Campus (Plants 5 to 8) by 2032, establishing a production capacity of 1,325,000 liters in Songdo alone. Including Rockville, the company's total global production capacity will increase to 1,385,000 liters. CEO John Rim commented, "As the antibody drug market is expected to continue growing, concerns about oversupply are minimal. In addition to monoclonal antibodies, multispecific antibody drugs are being actively developed, and the market is expanding into various fields such as immunology, oncology, central nervous system (CNS) diseases, and anti-aging."
Diversification of the business portfolio is also underway. Last year, Samsung Biologics began operating a dedicated antibody-drug conjugate (ADC) production facility, and is currently building an ADC drug product (DP) production line, scheduled for completion in the first quarter of 2027, to further strengthen its end-to-end support capabilities. The company is also expanding its portfolio into the contract research organization (CRO) sector, starting with the launch of the 'Samsung Organoid' service, and is simultaneously conducting research on next-generation modalities such as peptides and adeno-associated viruses (AAV). To support these modalities, the third Bio Campus began early-phase construction of certain facilities in May, with approximately 7 trillion won in investments expected to create more than 10,000 direct and indirect jobs and generate an economic impact of about 12 trillion won.
On the investment side, Samsung Biologics established its third Samsung Life Science Fund last month, worth 200 billion won. With the existing first fund (170 billion won) and second fund (72 billion won), the company has secured additional capacity. The most recent investment example is Cartography Biosciences, a U.S. antigen discovery platform company, in May. CEO John Rim said, "We will aggressively expand our investments in next-generation biotechnology sectors and plan to continuously broaden our global network and business collaboration opportunities through close partnerships with our portfolio companies."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Samsung Biologics has projected its sales growth guidance for this year at 15–20% higher than the previous year. CEO John Rim emphasized, "We will internalize the four key values of excellence in customer, operations, quality, and talent (the 4Es), and apply the three strategic pillars of simplification, standardization, and scalability (the 3Ss) to increase the speed of our business execution and enhance operational stability."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.